title: Effects of celecoxib and naproxen on renal function in the elderly.
abstract: OBJECTIVE
  To compare the effects of celecoxib, a cyclooxygenase 2-specific inhibitor, with the nonspecific cyclooxygenase 1 and 2 inhibitor naproxen on renal function in 29 healthy elderly subjects in a single-blind, randomized, crossover study.
  
  
  METHODS
  Subjects received either celecoxib, 200 mg twice daily, for 5 days followed by celecoxib, 400 mg twice daily, for the next 5 days, or they received naproxen, 500 mg twice daily, for 10 days. After a 7-day washout, subjects were crossed over to receive the other regimen.
  
  
  RESULTS
  After the first dose, the trend was for a greater decrease in glomerular filtration rate with naproxen (-5.31 mL/min per 1.73 m2) compared with celecoxib (-0.86 mL/min per 1.73 m2). The treatment difference became statistically significant on day 6 (-7.53 vs -1.11 mL/min per 1.73 m2 for naproxen and celecoxib, respectively; P=.004). Urinary prostaglandin E2 and 6-keto-prostaglandin F1alpha excretion was significantly reduced from baseline across the treatment interval with both celecoxib and naproxen (P< or =.04). There were no significant differences in prostaglandin excretion between these 2 agents (P> or =.07). Small, transient decreases (P<.05) in urinary sodium excretion were observed after the initiation of both celecoxib and naproxen treatment. Sodium excretion values returned to baseline by the end of the study.
  
  
  CONCLUSIONS
  The results indicate that cyclooxygenase 2-specific inhibition in healthy elderly subjects may spare renal hemodynamic function, although the effects on sodium excretion, as well as urinary prostaglandin E2 and 6-keto-prostaglandin F1alpha excretion, appear to be similar to those of nonspecific cyclooxygenase inhibitors such as naproxen.
authors.affiliation: Universal Clinical Research Center, Inc, Hunt Valley, MD 21030-1603, USA. huntvalley@aol.com
authors.forename: A
authors.initials: A
authors.lastname: Whelton
authors.forename: G
authors.initials: G
authors.lastname: Schulman
authors.forename: C
authors.initials: C
authors.lastname: Wallemark
authors.forename: E J
authors.initials: EJ
authors.lastname: Drower
authors.forename: P C
authors.initials: PC
authors.lastname: Isakson
authors.forename: K M
authors.initials: KM
authors.lastname: Verburg
authors.forename: G S
authors.initials: GS
authors.lastname: Geis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity*; D000068579:Celecoxib; D018592:Cross-Over Studies; D016861:Cyclooxygenase Inhibitors / Q000633:toxicity*; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests; D008297:Male; D009288:Naproxen / Q000633:toxicity*; D011720:Pyrazoles; D016037:Single-Blind Method; D013449:Sulfonamides / Q000633:toxicity*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D009288:Naproxen; D000068579:Celecoxib